{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T20:08:06Z","timestamp":1790712486262,"version":"4.1.0"},"reference-count":49,"publisher":"American Society for Microbiology","issue":"6","license":[{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"funder":[{"DOI":"10.13039\/100000060","name":"HHS | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["R01AI058145"],"award-info":[{"award-number":["R01AI058145"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2019,6]]},"abstract":"<jats:p>\n                    The fungal Cyp51-specific inhibitors VT-1161 and VT-1598 have emerged as promising new therapies to combat fungal infections, including\n                    <jats:italic>Candida<\/jats:italic>\n                    spp. To evaluate their\n                    <jats:italic>in vitro<\/jats:italic>\n                    activities compared to other azoles, MICs were determined by Clinical and Laboratory Standards Institute (CLSI) method for VT-1161, VT-1598, fluconazole, voriconazole, itraconazole, and posaconazole against 68\u2009\n                    <jats:named-content content-type=\"genus-species\">C. albicans<\/jats:named-content>\n                    clinical isolates well characterized for azole resistance mechanisms and mutant strains representing individual azole resistance mechanisms.\n                  <\/jats:p>","DOI":"10.1128\/aac.00341-19","type":"journal-article","created":{"date-parts":[[2019,3,22]],"date-time":"2019-03-22T06:36:35Z","timestamp":1553236595000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":41,"title":["<i>In Vitro<\/i>\n                    Activities of the Novel Investigational Tetrazoles VT-1161 and VT-1598 Compared to the Triazole Antifungals against Azole-Resistant Strains and Clinical Isolates of\n                    <i>Candida albicans<\/i>"],"prefix":"10.1128","volume":"63","author":[{"given":"Andrew T.","family":"Nishimoto","sequence":"first","affiliation":[{"name":"University of Tennessee Health Science Center, Memphis, Tennessee, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2225-5122","authenticated-orcid":false,"given":"Nathan P.","family":"Wiederhold","sequence":"additional","affiliation":[{"name":"University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie A.","family":"Flowers","sequence":"additional","affiliation":[{"name":"University of Tennessee Health Science Center, Memphis, Tennessee, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qing","family":"Zhang","sequence":"additional","affiliation":[{"name":"University of Tennessee Health Science Center, Memphis, Tennessee, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven L.","family":"Kelly","sequence":"additional","affiliation":[{"name":"Swansea University, Swansea, Wales, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joachim","family":"Morschh\u00e4user","sequence":"additional","affiliation":[{"name":"Universit\u00e4t W\u00fcrzburg, W\u00fcrzburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher M.","family":"Yates","sequence":"additional","affiliation":[{"name":"Viamet Pharmaceuticals, Inc., Durham, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William J.","family":"Hoekstra","sequence":"additional","affiliation":[{"name":"Viamet Pharmaceuticals, Inc., Durham, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Schotzinger","sequence":"additional","affiliation":[{"name":"Viamet Pharmaceuticals, Inc., Durham, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward P.","family":"Garvey","sequence":"additional","affiliation":[{"name":"Viamet Pharmaceuticals, Inc., Durham, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. David","family":"Rogers","sequence":"additional","affiliation":[{"name":"University of Tennessee Health Science Center, Memphis, Tennessee, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)60917-9"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.3109\/1040841X.2015.1091805"},{"key":"e_1_3_3_4_2","first-page":"20","article-title":"Epidemiology of oropharyngeal candidiasis in human immunodeficiency virus\/acquired immune deficiency syndrome patients and CD4+ counts","volume":"7","author":"Berberi A","year":"2015","unstructured":"Berberi A, Noujeim Z, Aoun G. 2015. Epidemiology of oropharyngeal candidiasis in human immunodeficiency virus\/acquired immune deficiency syndrome patients and CD4+ counts. J Int Oral Health 7:20\u201323.","journal-title":"J Int Oral Health"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(94)90300-X"},{"key":"e_1_3_3_6_2","first-page":"21","article-title":"Oral manifestations of HIV disease: a review","volume":"17","author":"Askinyte D","year":"2015","unstructured":"Askinyte D, Matulionyte R, Rimkevicius A. 2015. Oral manifestations of HIV disease: a review. Stomatologija 17:21\u201328.","journal-title":"Stomatologija"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1086\/421946"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01079-10"},{"key":"e_1_3_3_9_2","first-page":"938","article-title":"Antibiotic resistance threats in the United States: stepping back from the brink","volume":"89","author":"Solomon SL","year":"2014","unstructured":"Solomon SL, Oliver KB. 2014. Antibiotic resistance threats in the United States: stepping back from the brink. Am Fam Physician 89:938\u2013941.","journal-title":"Am Fam Physician"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.39.1.1"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1128\/jcm.32.9.2092-2098.1994"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01252-16"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jix179"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1534\/genetics.105.054767"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00926-08"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.0030164"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01106-07"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.5.1745-1752.2005"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1128\/EC.3.6.1391-1397.2004"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1128\/EC.00215-12"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.03470-14"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.42.2.241"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1574-6968.1999.tb08792.x"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1006\/bbrc.1999.1136"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0014-5793(96)01360-9"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1006\/bbrc.1995.1272"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00348-10"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dks186"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2014.05.068"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.03707-14"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2017.06.037"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02157-15"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01102-09"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkx410"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02258-17"},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dky242"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dky170"},{"key":"e_1_3_3_38_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00570-17"},{"key":"e_1_3_3_39_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M117.778308"},{"key":"e_1_3_3_40_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02114-18"},{"key":"e_1_3_3_41_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.05720-11"},{"key":"e_1_3_3_42_2","doi-asserted-by":"publisher","DOI":"10.1016\/0006-291X(89)91792-0"},{"key":"e_1_3_3_43_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.gene.2004.06.021"},{"key":"e_1_3_3_44_2","doi-asserted-by":"publisher","DOI":"10.1128\/aac.02586-18"},{"key":"e_1_3_3_45_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00064-14"},{"key":"e_1_3_3_46_2","doi-asserted-by":"publisher","DOI":"10.1111\/mmi.12327"},{"key":"e_1_3_3_47_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01343-10"},{"key":"e_1_3_3_48_2","volume-title":"CLSI document M27-A3","author":"Clinical and Laboratory Standards Institute","year":"2008","unstructured":"Clinical and Laboratory Standards Institute. 2008. Reference method for broth microdilution antifungal susceptibility testing of yeasts; approved standard, 3rd ed. CLSI document M27-A3. CLSI, Wayne, PA.","edition":"3"},{"key":"e_1_3_3_49_2","volume-title":"CLSI document M27-S4","author":"Clinical and Laboratory Standards Institute","year":"2012","unstructured":"Clinical and Laboratory Standards Institute. 2012. Reference method for broth microdilution antifungal susceptibility testing of yeasts; fourth informational supplement. CLSI document M27-S4. CLSI, Wayne, PA."},{"key":"e_1_3_3_50_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.02161-10"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00341-19","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00341-19","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T16:27:37Z","timestamp":1645460857000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.00341-19"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6]]},"references-count":49,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["10.1128\/AAC.00341-19"],"URL":"https:\/\/doi.org\/10.1128\/aac.00341-19","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6]]},"assertion":[{"value":"2019-02-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-03-16","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-05-24","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e00341-19"}}